BioWorld

Sep. 12, 2003

XOMA Plans Public Offering Of 9M Shares Following Panel Nod

Two days after an FDA advisory panel recommended approval of its partnered psoriasis drug Raptiva, XOMA Ltd. disclosed plans for a public offering of 9 million common shares. (BioWorld Today) Read More

Enforcing Rule May Hamstring Companies Seeking SBIR Help

The Lancet Explores Whether Depression, Schizophrenia Both Arise From Similar Genetic Causes

House, Senate Committee Agrees On New Reimbursement Rates

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...